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Association of prescribed opioid use between mother and child – a record-linkage study 
 
 
Absract 
 
Repeated use of prescribed opioids may lead to serious side effects, and it is important to examine risk 
factors for repeated use. The aim of this study was to investigate the association between maternal use 
of prescribed opioids and the use of prescribed opioids by their offspring.  
Data were drawn from two nationwide registers linked by the unique person identity numbers: the 
Norwegian Population and Housing Census in 2001 and the Norwegian Prescription Database (2004-
2009). The study population consisted of 97,574 adolescents aged 15-16 years in 2001 and their 
mothers. Repeated use of opioids was defined as filling 4+ and 15+ prescriptions during 2004-2009 by 
the offspring and mothers, respectively. Non-steroidal anti-inflammatory drugs (NSAIDs) are not 
potentially addictive, and were used as a reference analgesic drug group.   
The proportion of repeated users were higher among individuals whose mothers were registered with 
repeated use of opioids (8.4 %) compared to those with mothers without repeated use (2.4 %). Odds 
ratio was 3.1 (95% CI 2.7-3.6) when adjusted for mothers socioeconomic characteristics and the 
gender of the offspring. Low maternal socio-economic status increased the risk of repeated opioid use 
among their offspring. Maternal repeated use of NSAIDs increased the likelihood of repeated use of 
NSAIDs among offspring OR 1.8 (95% CI 1.7 – 2.0).  
 
 
Introduction 
 
Approximately 10 % of the Norwegian population received at least one opioid prescription for 
analgesia in 2009 [1]. This number has been increasing steadily over the years parallel to that of many 
other developed countries [2-10]. Increased efforts to address the assumed under-treatment of pain [11] 
may be one explanation, as extensive literature has shown that pain management is critical in order to 
achieve a favorable quality of life and improve medical outcome [12].  
Opioids have been the mainstay of pain treatment for thousands of years, and remain so today [13]. Its 
use has been and still is the focus of considerable debate due to its double-edged nature in terms 
therapeutic effect and serious side effects. Prescription opioids are highly effective when used properly 
[14] and are generally of low organ toxicity [15], but long-term use may be problematic because of the 
risk of addiction and misuse [14]. As it is unlikely that other classes of analgesic drugs will supersede 
the opioids in the very near future [11] it is important to identify those at high risk of developing 
problematic use of opioids before initiating treatment. One way to achieve this is to identify potential 
risk factors through epidemiological studies.   
Tsuang and colleagues recognize drug abuse as the culmination of a series of transitions of drug 
involvement from drug exposure to drug abuse. Drug abuse is preceded by a series of aquisititon steps 
that are necessary, but not sufficient for its development [16]. In developed countries therapeutic 
prescription of opioids adds to several steps of this chain of transitions; exposure, sporadic use and 
regular use. In that context, use of prescribed opioids plays an important role in the potential 
development of opioid abuse. Drugs abuse is thought to be a result of both genetic and environmental 
risk factors [17] which is supported by evidence that liability to illicit drug use and abuse aggregates in 
families [18]. To our knowledge, updated information on the influence of maternal use of prescribed 
opioids on prescribed use in their offspring, as a separate factor and in relation to other socioeconomic 
characteristics of the household, is limited. Therefore, it would be interesting – and important in a 
public health perspective – to investigate the reproduction of use of potentially addictive prescription 
drugs across generations. In Norway all citizens are assigned a unique 11-digit identification number, 
enabling linkage of available register information on drug use and socioeconomic characteristics, on an 
individual level [19]. It is also possible to link together members within the same household. Thus, 
based on nationwide register information, the aim of this study were to investigate the association 
between maternal use of prescribed opioids and the use of prescribed opiods by their offspring.  
 
 
Methods 
 
Data from The Population and Housing Census in 2001 (Census 2001) and the Norwegian Prescription 
Database (NorPD) were linked by using the unique 11-digit identification number, assigned to all 
individuals living in Norway. The record linkage was approved by the Norwegian Data Inspectorate 
and has been endorsed by the Regional Committee for Medical Research Ethics. 
 
The Population and Housing Census in 2001 – information on socioeconomic data 
Information on socioeconomic variables was retrieved from the nationwide population and housing 
census in Norway 2001 (Statistics Norway), performed November 3rd 2001 [20]. These variables are 
based on information from several administrative registers and contain information on all citizens 
living in Norway. Each individual is registered with a family number, enabling linkage of individuals 
within the same household.  In this context, individuals registered within the same household do not 
necessarily imply a biological family relationship between individuals. However, according to 
administrative registers 97.6 % of all children aged 0-17 years were living with their biological mother 
in Norway in 2000, at the time when the nationwide population and housing census was performed 
(Statistics Norway, 2001). Thus, adult females within the household will be referred to as mothers 
throughout the paper. The following variables were included in our analysis; mothers educational level, 
mothers activity status/labour force participation (employed, unemployed, in education, or receipt of 
national insurance benefit (disability-, retirement- or survivor pension)), marital status and age. 
 
The Norwegian Prescription Database – information on drug use 
Prescription data on analgesics during 2004–2009 were drawn from the NorPD, which covers all of 
Norway’s 4.8 million inhabitants. From January 1, 2004, all pharmacies in Norway have been obliged 
by law to send in electronic data on all redeemed prescriptions to the Norwegian Institute of Public 
Health [19]. NorPD contains information on all individuals who have received prescription drugs 
dispensed at pharmacies. All prescriptions, reimbursed or not, are stored in the database and the drugs 
are classified according to the anatomical therapeutic chemical (ATC) classification [21]. Data on 
opioids (ATC code N02A, main outcome variable) and non-steroidal anti-inflammatory drugs 
(NSAIDs, ATC code M01A, comparator) were used. Codeine, tramadol and dextropropoxyphene make 
up the weak N02A-opioids on the Norwegian marked, while the following strong N02A-opioids are 
available: morphine, hydromorphone, oxycodone, ketobemidone, phetidine, fentanyl, buprenorphine 
and tapentadol [22]. All N02A-opioids require prescriptions in Norway. Parallel to opioid drugs, 
NSAIDs have analgesic properties, but without the potential of being addictive. For this reason 
NSAIDs was used as reference. The data collected were: patient unique identifying number 
(encrypted), sex, age, age at death in case of death during the period, reimbursement code, the 
dispensing date and drug information (ATC code and number of defined daily doses (DDD)).  
The outcome variable, repeated use of opioids among offspring, was defined as receiving four or more 
opioid prescriptions during 2004–2009. By using this limit the repeated users consist of the highest 10 
percentile of opioid users. This cut-off was chosen to exclude users who received opioids for minor 
incidents such as dentistry and accidents. Repeated use among mothers’ was defined similarly by the 
highest 10 percentile, which gave a cut-off of 15 or more prescriptions. The same 10 percentile cut-off 
was used for the comparator. Reimbursement codes held in the database were used to identify patients 
receiving analgesics for cancer treatment.  
 
The study population 
Our analysis are restricted to data on citizens aged 15-16 years in 2001 and their mothers, participating 
in the nationwide population and housing census in Norway in 2001 and registered living in the same 
household that year. Children born in 1985-86 were selected (n= 108,163), of whom 285 were 
excluded because of situations such as; registered as parents themselves, not living in a private 
household, or living in cohabitation (Figure 1). The mother was defined as the oldest female person 
registered with the same family number as the 15-16 year old. This may have led to misclassifying 
grandmothers as mothers, but only 5 of the classified mothers were > 50 years at the time of the 
classified offspring’s birth. In total 657 were excluded, in whom the oldest female or male registered in 
the same household was 15 years or younger at time of birth.  In families with more than one 15-16 
year old, only the firstborn were included. The 107,221 15-16 year olds were distributed in 104,214 
families, in which 5,725 were excluded due to being registered living without their mothers and 915 
were excluded because the mother and/or their offspring received opioids to treat cancer related pain. 
The remaining 97,574 mother-child pairs were included in the analysis. The outcome variable, repeated 
use of opioids among offspring, was obtained during 2004-2009, when the children were 18-24 years 
of age. 
 
Statistics 
Odds ratios (OR) with 95% confidence intervals (CI) for variables potentially associated with opioid 
use, were estimated by logistic regression. Maternal characteristics such as mothers’ use of opioids, 
educational level, activity status/labour force participation, marital status and age were included in the 
model as independent variables together with the offspring’s gender. In total, 95,819 of the 97,574 
families included in the logistic regression had complete data on all the variables in the analysis (1.8 % 
missing). All analyses were done using SPSS 15.0 for Windows. Cochrane-Armitage test for linear 
trend was used to examine a possible dose-response relationship between the proportion of offspring 
opioid users with the number of maternal opioid prescriptions. Level of significance was set to p<0.05. 
 
 
Results 
 
Table 1 shows the socioeconomic characteristics of the mothers according to opioid use status. Overall 
a socioeconomic gradient was observed between mothers who were repeated opioid users during 2004-
2009 compared to the rest of the study-population. Educational level was significantly lower among 
maternal users, a larger proportion of the maternal users were receivers of a disability pension, fewer 
were registered as employed as compared to the non users, and a higher proportion of the maternal 
users were not married (or a registered partner).  
 
Of the 97,574 offspring eligible for analysis, 2,519 (2.6 %) were classified as repeated users of opioids 
during 2004-2009. The proportion of repeated users were higher among individuals whose mothers 
were registered with repeated use of opioids (8.4 %) compared to those with mothers without repeated 
use (2.4 %) (Table 2). Odds ratio was 3.7 decreasing to 3.1 when adjusting for other variables. Several 
of the variables based on characteristics of the mothers were independently associated with repeated 
opioid use among offspring: lower educational level, disability pensioner and not having a registered 
partner or husband. In addition, female offspring were more likely to use opioids repeatedly compared 
to males (Table 2).  
 
A possible dose-response relationship was observed, with the proportion of offspring opioid users 
increasing with more frequent maternal opioid use. This was evident for various degrees of offspring 
opioid use (p<0.001 for all categories) (Figure 2).  
 
A total of 5,267 offspring (5.4 %) were repeated users of NSAIDs during 2004-2009. Maternal 
repeated use of NSAIDs increased the likelihood of repeated use of NSAIDs among offspring OR 1.8 
(1.7 – 2.0) (Table 3). Mothers’ socioeconomic status was also predictive of repeated use of NSAIDs. 
 
 
Discussion 
 
Our study showed that repeated maternal use of opioids was associated with a threefold increased risk 
of repeated opioid use among their offspring. The proportion of offspring opioid users increased with 
increasing maternal opioid use, suggesting a dose-response relationship.  
The association observed for repeated maternal and offspring use of NSAIDs may indicate that 
reproduction of drug use patterns is present for all classes of analgesics drugs. This may be due to 
inherited pain thresholds and/or habits of how to cope with- and treat pain.  
 
We are not aware of other studies which specifically have examined the association between prescribed 
maternal and offspring opioid use. However, our results are in agreement with the findings in studies 
examining the association between parental and offspring illicit opioid use [17]. Evidence does suggest 
that the liability to illicit drug use and abuse aggregates in families, a phenomenon that may be 
explained by both genetic and environmental factors [18]. This might as well be the case with 
potentially addictive prescription drugs, as shown by a recent study conducted by Hartz and colleagues 
which found an association between maternal and offspring use of benzodiazepines/z-hypnotics, OR 
1.9 (1.8 – 2.0) [23]. It is however, very important to emphasize that our cut-off points of 15+ 
prescriptions of opioids among mothers and 4+ prescriptions among their offspring do not indicate 
problematic use of opioids or abuse. It is not possible to separate appropriate from problematic use 
based on our data. 
  
In terms of genetics, inheritable diseases that require or make opioid treatment more probable can 
explain some of the association observed in our study. In addition, inherited differences in 
pharmacokinetics and effect of opioids that increases the vulnerability to the development of 
problematic opioid use may be another contributing factor. 
When taking environmental factors into account, being exposed to maternal opioid use may, as 
proposed by Tsuang, act as the first step on the way to opioid drug use. This is evident for illicit use 
and may also be true for therapeutic use. Additionally problematic use among offspring may be 
explained by negative life events associated with problematic maternal use [17]. 
 
Maternal characteristics indicating a lower socio-economic position (low education and disability 
pension) were independently associated to use of opioids among offspring. Considering the potentially 
harmful effect of these drugs, our results are in line with former research into health inequalities 
showing that lower socio-economic status is correlated with poorer habits of health behavior [24-25]. 
Thus, use of potentially addictive drugs may constitute yet another type of poor health behaviour, along 
with making unhealthy food choices, physical inactivity and smoking which is documented to be more 
prevalent among socio-economic disadvantaged groups [26]. 
Medicine use among young people in general is documented to be widespread and increasing [27-30]. 
Use of drugs for a variety of complaints among young females in particular, grows considerably during 
the teenage years [31]. One qualitative study exploring the use of analgesics revealed that young 
women relied on analgesics to cope with perceived pressures and social anxieties, as part of their 
attempt to meet everyday goals involving performance and participation [32]. Our study adds to the 
evidence that females are at a higher risk of becoming repeated users compared to men.   
 
Even though many relevant confounders associated with opioid use are included in our model, we 
don’t have any data on pain, the main indication of use, among the offspring. Thus, analgesic drug use 
increases significantly with more self-reported pain in this age group [33]. As a result, the observed 
difference may be explained by more cases of pain among offspring with mothers repeatedly using 
opioids. 
We chose a 90-percentile cut-off for repeated use of opioids in order to exclude users who received 
opioids for minor incidents such as dentistry and accidents. A recent study from the United States 
showed that dentists were the main prescribers of opioids for patients aged 10-19 (31 %) and the 
second most frequent among those aged 20-29 (17 %) [10]. Lack of information on indication for 
opioid treatment makes it hard to determine whether our chosen cut-off point is ideal. In total, 24.5 % 
of the offspring retrieved at least one prescription on an opioid during the study period, while only 2.7 
% received four or more prescriptions. Thus, repeated opioid use constituted about 10 % of the 
offspring opioid users in this study. 
In this study repeated use of opioid included all opioids regardless of subclass. A more detailed 
analysis of patterns of use, including distinction between stronger/weaker and long-acting /short-acting 
opioids would have been desirable. Use of codeine in combination with paracetamol and tramadol do 
account for nearly the entire opioid consumption among younger generations [34]. As a result we could 
not stratify for strong/weak and long-acting/short-acting opioids due to few strong and long-acting 
opioid users. 
.  
Compliance is always an issue when using prescription based data. We don’t have any data on the 
extent to which purchased drugs were actually taken. However, our data are based on dispensed drugs 
rather than prescribed which at least rules out primary non-compliance [35]. Finally our reference drug 
group may not be ideal as NSAIDs can be used either with or without a prescription, and we lack 
information on non-prescription use. 
Other weaknesses include: 1) maternal characteristic valid in 2001 may have changed when data on 
drug use was collected in 2004-2009, 2) we do not know whether mother’s drug use precedes that of 
the child, or vice versa. 
 
During our six year study period 2.6 % of the offspring were classified as repeated users of opioids. 
Considering that cancer patients are excluded and that diseases requiring opioid therapy are quite rare 
in this age group, this number is high. In order to minimize the risk of problematic use of opioids, 
identifying factors associated to use is important. Our study suggests that repeated maternal use of 
opioids may be associated with repeated use of opioids among offspring.  
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Figures and tables 
 
Figure 1: Flow chart of the study population. Collected from the Population and Housing Census in 
2001 
 
 
Figure 2: The proportion of opioid users (various degrees) among offspring based on maternal use of 
opioids  
 
 Table 1. Socioeconomic characteristics of mothers with 15-16 year old children in 2001, according to use of 
opioids in 2004-2009. 
 
 Repeated maternal use of opioids during 2004-091  
 No (N = 94423) Yes (N = 4066) p-value 
Mother age (mean(SD))  43.0 (5.0) 42.0 (5.3) < 0.001 
Mother educational level 2   < 0.001 
   low (junior high school) 11.4 % (10544/92763) 21.8 % (865/3962)  
   medium (senior high school) 58.8 % (54561/92763) 63.3 % (2508/3962)  
   high (college, university) 29.8 % (27658/92763) 14.9 % (589/3962)  
Mother actitivity status 3   < 0.001 
   employed  83.9 % (79206/94413) 59.3 % (2411/4066)  
   unemployed  1.3 % (1219/94413) 2.0 % (82/4066)  
   student 1.5 % (1402/94413) 2.0 % (80/4066)  
   disability pensioner 3.3 % (3099/94413) 19.6 % (796/4066)  
   old-age pensioner 0.3 % (282/94413) 0.4 % (16/4066)  
   other 9.7 % (9205/94413) 16.7 % (681/4066)  
Mother married/registered partner 74.9 % (70720/94423) 60.0 % (2441/4066) < 0.001 
1 Repeated use among the mothers equals 15+ prescriptions during 2004-2009 (Upper 10 percentile) 
2 1764 missing (1.8 %) 
3 10 missing (0.01 %) 
  
Table 2: Maternal opioid use, and other factors associated with use of opioids among offspring 
 Repeated use of opioids among  offspring  (2004-2009)1 
 
Prevalence 
% (n) 
Unadjusted OR 
OR (95 % CI) 
p-value 
Adjusted OR2 
OR (95 % CI) 
p-value 
Repeated maternal use of opioids3      
No  2.4 % (2172/92220) 1.0 - 1.0 - 
Yes  8.4 % (304/3599) 3.7 (3.3 – 4.2) 0.000 3.1 (2.7 – 3.6) 0.000 
Gender (offspring)      
Male 1.9 % (940/48940) 1.0 - 1.0 - 
Female 3.3 % (1536/46879) 1.7 (1.6 – 1.8) 0.000 1.7 (1.6 – 1.9) 0.000 
Mother’s educational level      
High (college, university)  1.7 % (476/28011) 1.0 - 1.0 - 
Medium (senior high school)  2.8 % (1598/56530) 1.7 (1.5 – 1.9) 0.000 1.4 (1.3 – 1.6) 0.000 
Low (junior high school)  3.6 % (402/11278) 2.1 (1.9 – 2.4) 0.000 1.7 (1.4 – 1.9) 0.000 
Mother’s activity status      
Employed (n = 80929) 2.4 % (1920/80278) 1.0 - 1.0 - 
Unemployed (n = 1241) 3.4 % (42/1225) 1.5 (1.1 – 2.0) 0.016 1.1 (0.8 – 1.5) 0.463 
Student (n = 1437) 2.8 % (40/1430) 1.2 (0.9 – 1.6) 0.245 1.0 (0.7 – 1.3) 0.864 
Old-age pensioner (n = 279) 3.6 % (10/275) 1.6 (0.9 – 2.9) 0.130 1.2 (0.6 – 2.2) 0.611 
Disability pensioner (n = 3800) 4.6 % (168/3688) 2.0 (1.7 – 2.4) 0.000 1.4 (1.2 – 1.6) 0.000 
Other (n = 9032) 3.3 % (296/8923) 1.4 (1.2 – 1.6) 0.000 1.1 (1.0 – 1.3) 0.033 
Mother married / registered partner      
Yes  2.3 % (1608/71169) 1.0 - 1.0 - 
No  3.5 % (868/24650) 1.6 (1.5 – 1.7) 0.000 1.4 (1.3 – 1.5) 0.000 
1 Repeated use among the offspring equals 4+ prescriptions during 2004-2009 (Upper 10 percentile) 
2 Adjusted for gender, maternal use of opioids. mother’s educational level, mother’s activity status, age and if mother is married or has a 
registered partner 
3 Repeated use among the mothers equals 15+ prescriptions during 2004-2009 (Upper 10 percentile) 
  
Table 3: Maternal use, and other factors associated with use of NSAIDs among offspring 
 Repeated use of NSAIDs among offspring (2004-2009)1 
 
Prevalence 
% (n) 
Unajusted OR 
OR (95 % CI) 
p-value 
Adjusted OR2 
OR (95 % CI) 
p-value 
Repeated mat. use of NSAIDs3      
No  5.1 % (4526/88824) 1.0 - 1.0 - 
Yes  9.4 % (661/6995) 1.9 (1.8 – 2.1) 0.000 1.8 (1.7 – 2.0) 0.000 
Gender (offspring)      
Male 3.6 % (1776/48940) 1.0 - 1.0 - 
Female 7.3 % (3411/46879) 2.1 (1.1 – 1.3) 0.000 2.1 (2.0 – 2.2) 0.000 
Mother’s educational level      
High (college, university)  3.6 % (1021/28011) 1.0 - 1.0 - 
Medium (senior high school)  6.0 % (3399/56530) 1.7 (1.6 – 1.8) 0.000 1.6 (1.4 – 1-7) 0.000 
Low (junior high school)  6.8 % (767/11278) 1.9 (1.8 – 2.1) 0.000 1.7 (1.5 – 1.9) 0.000 
Mother’s activity status      
Employed (n = 80929) 5.2 % (4200/80278) 1.0 - 1.0 - 
Unemployed (n = 1241) 5.5 % (67/1225) 1.0 (0.8 – 1.3) 0.721 0.9 (0.7 – 1.1) 0.354 
Student (n = 1437) 4.5 % (64/1430) 0.9 (0.7 – 1.1) 0.200 0.8 (0.6 – 1.0) 0.038 
Old-age pensioner (n = 279) 6.9 % (19/275) 1.3 (0.8 – 2.1) 0.226 1.2 (0.7 – 1.9) 0.447 
Disability pensioner (n = 3800) 8.0 % (296/3688) 1.6 (1.4 – 1.8) 0.000 1.4 (1.2 – 1.5) 0.000 
Other (n = 9032) 6.1 % (541/8923) 1.1 (1.0 – 1.3) 0.003 1.0 (0.9 – 1.1) 0.478 
Mother married / registered partner      
Yes  5.2 % (3669/71169) 1.0 - 1.0 - 
No  6.2 % (1518/24650) 1.2 (1.1 – 1.3) 0.000 1.1 (1.0 – 1.2) 0.001 
1 Repeated use among the offspring equals 4+ prescriptions during 2004-2009 (Upper 10 percentile) 
2 Adjusted for gender, maternal use of NSAIDs. mother’s educational level, mother’s activity status, age and if mother is married or 
has a registered partner 
3  Repeated use among the mothers equals 15+ prescriptions during 2004-2009 (Upper 10 percentile) 
